A multicentre randomised trial to compare the effect of two blinded doses of CASODEX (AstraZeneca 176,334; 100 mg and 150 mg orally daily) and castration in the treatment of advanced carcinoma of the prostate

Study identifier:176334-0307

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A multicentre randomised trial to compare the effect of two blinded doses of CASODEX (AstraZeneca 176,334; 100 mg and 150 mg orally daily) and castration in the treatment of advanced carcinoma of the prostate

Medical condition

prostate cancer

Phase

Phase 3

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria